ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "genomics"

  • Abstract Number: 0904 • ACR Convergence 2024

    Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing

    Yuriy Baglaenko1, MIchelle Curtis2, Majd Al Suqri3, Ryan Agnew3, Aparna Nathan4, Hafsa Mire4, Annelise Yoo Mah-Som3, David Liu5, Gregory Newby6 and Soumya Raychaudhuri3, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Broad Institute, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Harvard Medical School, Boston, MA, 5Broad Institute, Cambridge, MA, 6Johns Hopkins, Baltimore, MD

    Background/Purpose: Genetic studies have identified thousands of individual disease-associated non-coding alleles, but identification of the causal alleles and their functions remain critical bottlenecks. Even though…
  • Abstract Number: 1810 • ACR Convergence 2024

    Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus

    Ksenia Anufrieva1, Rochelle Castillo2, Ce Gao2, Jessica Liu2, Neda Shahriari2, Kimberly Hashemi2, Dustin Taylor3, Rachael Rowley2, Elizabeth Rainone2, Avery LaChance2, Rachel Gate4, ilya Korsunsky2, Ruth Ann Vleugels5 and Kevin Wei6, 1BWH, Cambridge, MA, 2Brigham and Women's Hospital, Boston, MA, 3Vanderbilt University Medical Center, Nashville, TN, 410x Genomics, Pleasanton, CA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA

    Background/Purpose: Reliable and effective treatments for refractory cutaneous lupus erythematosus (CLE) remained elusive until the arrival of anifrolumab, a monoclonal antibody targeting the type I…
  • Abstract Number: 0022 • ACR Convergence 2024

    Transcriptomic Characterization of Knee Capsule Fibroblasts and Mesenchymal Stromal Cells Reveals an Association Between Flexion Contracture and Alterations in Immune Pathways in People with End-stage OA

    Odette Laneuville1, Daniel Stratis1, Robert Feibel2, Guy Trudel3 and T Mark Campbell4, 1University of Ottawa, Ottawa, ON, Canada, 2The Ottawa Hospital, Ottawa, ON, Canada, 3Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4Bruyère Research Institute, Ottawa, ON, Canada

    Background/Purpose: Over 10% of adults have symptomatic knee OA but no disease-modifying interventions exist. A flexion contracture (loss of extension; FC) presents in 1/3 of…
  • Abstract Number: 0907 • ACR Convergence 2024

    Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol

    Niamh Fanning1, Murray Cadzow2, Ruth Topless3, Chris Frampton4, Nicola Dalbeth5, Tony Merriman6 and Lisa Stamp4, 1University of Otago, Christchurch, New Zealand, 2University of Otago, Dunedin 9054, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5University of Auckland, Auckland, New Zealand, 6University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
  • Abstract Number: 1819 • ACR Convergence 2024

    Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis

    Ye Jin Jeong1, Gayathri Guru Murthy1, Gaochan Wang1, Tahia Rahman1 and Benjamin Korman2, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester, Rochester, NY

    Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…
  • Abstract Number: 0028 • ACR Convergence 2024

    Human Meniscus Histopathological and Transcriptomic Changes at Early and Advanced Stages of Knee Osteoarthritis

    Takuya Sakamoto1, Hannah Swahn1, Merissa Olmer1, Rachel Miller2, Anne-Marie Malfait3 and Martin Lotz1, 1Scripps Research Institute, La Jolla, CA, 2Rush University Medical Center, Chicago, IL, 3Rush University Medical Center, Division of Rheumatology, Chicago, IL

    Background/Purpose: The knee menisci are essential elements in joint biomechanics and meniscus damage is a driver of cartilage destruction and knee osteoarthritis. Meniscus damage and…
  • Abstract Number: 0909 • ACR Convergence 2024

    Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…
  • Abstract Number: 1822 • ACR Convergence 2024

    Analysis of Differential Activation of Lysophosphatidic Acid Regulated Genes in Diffuse and Limited Cutaneous Systemic Sclerosis

    Medha Kanitkar1, Philip Yee2, Stefano Rodolfi1, Kristina Clark3, Voon Ong4 and Christopher Denton5, 1University College London, London, United Kingdom, 2UCL, London, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University College London, London, England, United Kingdom, 5University College London, Northwood, United Kingdom

    Background/Purpose: Lysophosphatidic Acid (LPA) is a lipid mediator implicated in the pathogenesis of SSc and  idiopathic pulmonary fibrosis. Phase 2 clinical trials targeting this biological…
  • Abstract Number: 0063 • ACR Convergence 2024

    Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils

    Rayan Najjar1, Noga Rogel2 and Tomas Mustelin3, 1University of Washington, Seattle, 2University of Washinton, Seattle, 3University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
  • Abstract Number: 0911 • ACR Convergence 2024

    Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

    David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
  • Abstract Number: 1823 • ACR Convergence 2024

    Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts

    Zhiyun Gong1, Rezvan Parvizi2, Helen Jarnagin1, Haobin Chen3, Madeline Morrisson4, Tammara Wood5, Monique Hinchcliff6 and Michael Whitfield2, 1Dartmouth College, Lebanon, NH, 2Geisel School of Medicine at Dartmouth, Hanover, NH, 3Dartmouth, Lebanon, NH, 4Geisel School of Medicine at Dartmouth College, Hanover, NH, 5Dartmouth, Hanover, NH, 6Yale School of Medicine, Westport, CT

    Background/Purpose: Systemic Sclerosis (SSc) is a molecularly heterogeneous disease. Distinct subtypes of patients have been identified based on gene expression in skin. In this study,…
  • Abstract Number: 0479 • ACR Convergence 2024

    Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis

    Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
  • Abstract Number: 0913 • ACR Convergence 2024

    The Association Between PTPN2 and Leukopenia in New Users of Azathioprine

    Puran Nepal1, Laura L. Daniel2, Jacy Zanussi2, Alyson L. Dickson3, Wei-Qi Wei3, Adriana M. Hung4, Nancy J. Cox3, Vivian K. Kawai3, Jonathan D. Mosley3, C. Michael Stein3, QiPing Feng3, Ge Liu3, Ran Tao3 and Cecilia P. Chung2, 1Vanderbilt University Medical Center, Vanderbilt, TN, 2University of Miami, Miami, FL, 3Vanderbilt University Medical Center, Nashville, TN, 4Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Leukopenia is a common dose-dependent side effect of azathioprine and often results in discontinuation of the drug. Variants in TPMT and NUDT15 have been…
  • Abstract Number: 1829 • ACR Convergence 2024

    Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis

    Philip Yee1, Medha Kanitkar2, Kristina Clark3, Voon Ong1 and Christopher Denton4, 1University College London, London, England, United Kingdom, 2University College London, London, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University College London, Northwood, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) displays significant heterogeneity. Those with limited cutaneous systemic sclerosis (lcSSc) experience significant systemic organ involvement similar to those with diffuse cutaneous…
  • Abstract Number: 0521 • ACR Convergence 2024

    Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis

    Ernest Choy1, Maria López Lasanta2, Paloma Vela-Casasempere3, Antonio Fernandez Nebro4, Santos Castañeda5, Carlos Marras6, Jaime Calvo-Alén7, Jesus Tornero8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, José Manuel Carrascosa12, Eduardo Fonseca13, Luis Bujanda14, Valle García15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Pere Santamaria19, Richard M Myers20, yolanda Guillen21, Sergio H Martínez-Mateu22, Sara Marsal23 and Antonio Julia24, and IMID Consortium, 1Cardiff University School of Medicine, Cardiff, United Kingdom, 2Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 3Hospital General Universitario Alicante, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 7Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 8Hospital Universitario de Guadalajara, Guadalajara, Spain, 9Hospital Clinic an IDIBAPS, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Universitario de Donostia, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Córdoba, Spain, 16Charité – Universitätsmedizin Berlin, Berlin, Germany, 17University of Verona, Verona, Italy, 18Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, 19Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 20HudsonAlpha Institute for Biotechnology, Huntsville, AL, 21Imidomics, Inc, Barcelona, Spain, 22IMIDOMICs, Barcelona, Spain, 23Vall Hebron Hospital Research Institute, Barcelona, Spain, 24Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology